Current News

Contact | Print version | PDF version | Send article | RSS-Feed

Painceptor Pharma gains patent for lead drug

04 Oct 2006 - PainCeptor Pharma Corp., a biopharmaceutical company focused on the development of novel therapeutics for the treatment of chronic and acute pain, announced that it has been awarded a series of milestone patents for its two lead drug development programs, NGF (nerve growth factor) and ASIC (acid sensing ion channel) antagonists.
 
The four patents granted PainCeptor are: 1. 'Neurotrophin Antagonists for the Treatment of Epilepsy, Alzheimer's Disease and Pain'' - patent allowed in Europe (#0930883) and Israel (#129475)
 
2. 'Method of Inhibiting Neurotrophin-Receptor Binding'' - patent issued in Australia (#781888)
 
3. "DNA Encoding a Human Proton-Gated Ion Channel and Uses Thereof'' - patent allowed in Europe (#EP-B-1025226)
 
4. "Method of Inhibiting Neurotrophin-Receptor Binding'' - US Divisional Patent allowed
 
These patents bring the total of PainCeptor's intellectual property portfolio to 39 issued patents; with an additional 45 patent applications under examination; and a further 10 provisional applications pending.